Lilly has more positive data on its weekly insulin
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Morning! Today, we talk about some highly anticipated data from Summit Therapeutics that could show how its bispecific antibody drug outperformed Keytruda in a head-to-head lung cancer trial. Also, positive data from Lilly on its weekly insulin, and we explore amylin as a target for obesity.
Read Original Article: Lilly has more positive data on its weekly insulin »
